Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
FDA geeft dasatinib review-prioriteit bij behandeling pediatrische CML
okt 2017 | Leukemie